Heart Diseases Clinical Trials

A listing of 36 Heart Diseases clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Conditions

Heart Diseases

13 - 24 of 36

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

There are currently 36 active clinical trials seeking participants for Heart Diseases research studies. The states with the highest number of trials for Heart Diseases participants are New York, Pennsylvania, California and Texas.

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Trial

Chronic Cough Study

Recruiting

Are you tired of living with chronic cough? The ASPIRE Study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough. You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you.

Conditions:

Chronic Cough

Refractory or Unexplained Chronic Cough

Cough

Asthma

Allergic Asthma

Learn More

Featured Trial

Studying an Investigational Virus Vaccine

Recruiting

The main objectives of this study are to assess the safety and effectiveness of an investigational vaccine aimed at preventing norovirus, commonly known as the stomach flu. Participants will be randomly assigned to receive either the investigational vaccine or a placebo. Should you express interest, you will be contacted directly by the research site, which will provide further details and answer any questions you may have about study requirements, risks/benefits, and any compensation.

Conditions:

Healthy

Interested in vaccine studies

All Conditions

Preventative Trials

Learn More

Featured Trial

Respiratory Syncytial Virus (RSV) Treatment Study

Recruiting

We’re seeking volunteers to participate in a RSV treatment study.
Our site is now enrolling ages 18+ years old in a research study evaluating an investigational RSV treatment. Compensation is available for participation. To be eligible, you must be 18 or older, experiencing current symptoms (such as nasal congestion, cough, or wheezing), and meet at least one of the following:

- Asthma
- Chronic lung disease
- COPD
- Heart disease
- Age 60 or older

Conditions:

RSV

Respiratory Syncytial Virus (RSV)

Healthy

Healthy Volunteers

Healthy Subjects

Learn More

The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing

NCT01280825

Recruiting

The purpose of this study is to collect DNA samples from patients undergoing routine care at the University of Chicago. These samples will be tested for differences in genes that may suggest greater risk of side effects or chance of increased benefit from certain medications. The results will be made available to the patient's treating physician and the researchers will track whether or not this information is used in routine health care.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/04/2025

Locations: University of Chicago Medical Center, Chicago, Illinois

Conditions: Patients Undergoing Routine Health Care, Heart Diseases, Inflammatory Bowel Diseases, Autoimmune Disease, Inflammatory Disease, Blood Coagulation Disorders, Hepatitis C, Non-Metastatic Neoplasm

Learn More ›

Prescribed Sternal Precautions vs. Self-Guided Restrictive Care (PEEERC)

NCT05206929

Recruiting

Our study aims to compare postoperative outcomes, postoperative pain and postoperative quality of lives in patients who receive the standard sternal precautions to those in patients who received self-managed sternal precautions following sternotomy for cardiac surgeries. The purpose of the study is to see if self-managed sternal precautions following sternotomy for cardiac surgeries lead to better quality of lives while maintaining same postoperative pain and rate of postoperative adverse events... Read More

Gender:

ALL

Ages:

Between 18 years and 70 years

Trial Updated:

02/03/2025

Locations: The University of Chicago, Chicago, Illinois

Conditions: Surgery, Heart Diseases, Heart Failure, Cardiac Valve Disease

Learn More ›

Development of a Culturally Tailored Resilience-building Intervention for Chinese American's Advance Care Planning Discussions

NCT06247215

Recruiting

Less than 15% of Chinese Americans complete advance directives. That is less than half of the 37% completion rate in the US general population. This disparity in the use of advance care planning between White Americans and Chinese Americans may extend to disparities in end-of-life care. To address such disparities in end-of-life care, we will develop and assess the acceptability of a culturally tailored resilience-building intervention to help Chinese Americans with cancer or heart disease and t... Read More

Gender:

ALL

Ages:

Between 18 years and 80 years

Trial Updated:

01/17/2025

Locations: University of Illinois Chicago, Chicago, Illinois

Conditions: Advance Care Planning, Neoplasms, Heart Diseases

Learn More ›

Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure

NCT06310031

Recruiting

The goal of this study is to evaluate the safety and efficacy of the BrioVAD System by demonstrating non-inferiority to the HeartMate 3 Left Ventricular Assist System when used for the treatment of advanced, refractory, left ventricular heart failure.

Gender:

ALL

Ages:

Between 18 years and 100 years

Trial Updated:

01/15/2025

Locations: Emory University, Atlanta, Georgia +6 locations

Conditions: Cardiovascular Diseases, Heart Diseases, Heart Failure

Learn More ›

Health Electronic Assessment of Risks and Trends Using Biometric Equipment and Technology

NCT06753045

Recruiting

This is a phase 0, non-interventional, longitudinal, electronic data capture (EDC) study to facilitate the HEARTBEAT Study project has set out to explore the potential use of smartwatches in collecting and analyzing biometric data to improve the detection, identification, and understanding of cardiovascular diseases and related conditions by SAMSUNG and Tulane. The study will include up to ten thousand adult subjects tasked with wearing a smartwatch to collect digital biomarker data over a 1 yea... Read More

Gender:

ALL

Ages:

Between 18 years and 120 years

Trial Updated:

01/02/2025

Locations: East Jefferson General Hospital, New Orleans, Louisiana +2 locations

Conditions: Heart Diseases

Learn More ›

A Preliminary Study for INFORMED

NCT05585125

Recruiting

Investigators will determine whether N-of-1 trials, as a pragmatic, participant-centered approach to medication optimization that can overcome key barriers of deprescribing, can lead to increased participant confidence regarding their preference to continue or discontinue beta-blockers in older adults with Heart Failure with Preserved Ejection Fraction (HFpEF).

Gender:

ALL

Ages:

65 years and above

Trial Updated:

12/06/2024

Locations: Weill Cornell Medicine, New York, New York

Conditions: Heart Failure, Heart Failure, Diastolic, Heart Failure With Preserved Ejection Fraction, Cardiac Failure, Heart Diseases

Learn More ›

Food is Medicine for Patients with Heart Failure

NCT06540118

Recruiting

This study will look at the effects of providing medically tailored meals (MTMs) to people with heart disease for twelve weeks. The primary outcome of the study is the quality of the diet being consumed in week 12 of the study, as determined by the "Healthy Eating Index."

Gender:

ALL

Ages:

18 years and above

Trial Updated:

11/27/2024

Locations: University of California San Diego, La Jolla, California +1 locations

Conditions: Heart Failure, Heart Failure，Congestive, Heart Diseases

Learn More ›

South Asians and Coronary Plaque Registry

NCT05367297

Recruiting

Individuals who self-report as SAs will be recruited to participate in this registry as well as non-SA controls for comparison. All individuals who consent to participate will 1) complete a survey assessing demographics, medical history, family medical history; 2) have blood collection; 3) and CCTA assessment. These data will be combined with clinical data from the electronic health record and, if applicable, the Dallas Hearts and Mind Study and other research studies, for research purposes. The... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

08/15/2024

Locations: University of Texas Southwestern Medical Center, Dallas, Texas

Conditions: Coronary Artery Disease, Heart Diseases

Learn More ›

Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women

NCT04124120

Recruiting

The central hypothesis of ROMA:Women is that the use of multiple arterial grafting (MAG) will improve clinical outcomes and quality of life (QOL) compared to single arterial grfating (SAG). The specific aims of ROMA:Women are: Aim 1: Determine the impact of MAG vs SAG on major adverse cardiac and cerebrovascular events in women undergoing coronary artery bypass grfating (CABG). The investigators will compare major adverse cardiac and cerebrovascular events (death, stroke, non-procedural myocardial infarction, repeat revascularization, and hospital readmission for acute coronary syndrome or heart failure) in a cohort of 2,000 women randomized 1:1 to MAG or SAG (690 from the parent ROMA trial + 1,310 from ROMA:Women). Differences by important clinical and surgical subgroups (patients younger or older than 70 years, diabetics, racial and ethnic minorities, on vs off pump CABG, type of arterial grafts used) will also be evaluated. The women enrolled in the ongoing ROMA trial (anticipated to be approximately 690) will be included in ROMA:Women, increasing efficiency and reducing enrollment time. Hypothesis 1.0. MAG will reduce the incidence of major adverse cardiac and cerebrovascular events. Hypothesis 1.1. The improvement with MAG will be consistent across key subgroups. Aim 2: Determine the impact of MAG vs SAG on generic and disease-specific QOL, physical and mental health symptoms in women undergoing CABG. The investigators will compare generic (SF-12, EQ-5D) and disease-specific (Seattle Angina Questionnaire) QOL and physical and mental health symptoms (PROMIS-29) in a sub-cohort of 500 women randomized 1:1 to MAG or SAG (including those enrolled in ROMA:QOL). Differences by important subgroups (as defined above) will also be evaluated. Hypothesis 2.0. MAG will improve generic and disease-specific QOL compared to SAG. Hypothesis 2.1. MAG will improve physical and mental health symptoms compared to SAG. Hypothesis 2.2. The improvement with MAG will be consistent across key subgroups. Read Less

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

08/05/2024

Locations: Cedars-Sinai Medical Center, Los Angeles, California +123 locations

Cedars-Sinai Medical Center, Los Angeles, California

University of Colorado, Aurora, Colorado

Yale University Hospital, New Haven, Connecticut

Emory University, Atlanta, Georgia

University of Chicago, Chicago, Illinois

Johns Hopkins University, Baltimore, Maryland

Baystate Health, Springfield, Massachusetts

University of Massachusetts Chan Medical School, Worcester, Massachusetts

Washington University in St. Louis, Saint Louis, Missouri

Nebraska Heart Hospital, Lincoln, Nebraska

Methodist Physicians Health, Omaha, Nebraska

University of Nebraska Medical Center, Omaha, Nebraska

Englewood Health, Englewood, New Jersey

Newark Beth Israel Medical Center, Newark, New Jersey

The Valley Hospital, Ridgewood, New Jersey

NewYork-Presbyterian Brooklyn Methodist Hospital, Brooklyn, New York

Weill Cornell Medicine, New York, New York

Icahn School of Medicine, Mount Sinai, New York, New York

Columbia University Medical Center, New York, New York

Lenox Hill Hospital, New York, New York

New York Presbyterian Queens, Queens, New York

Duke University, Durham, North Carolina

Cleveland Clinic Foundation, Cleveland, Ohio

Ohio State University, Columbus, Ohio

University of Pennsylvania, Philadelphia, Pennsylvania

Allegheny General Hospital, Pittsburgh, Pennsylvania

Lankenau Medical Center, Wynnewood, Pennsylvania

Rhode Island Hospital, Providence, Rhode Island

Baylor Scott & White Research Institute, Dallas, Texas

Baylor College of Medicine, Houston, Texas

UT Health San Antonio, San Antonio, Texas

University of Utah, Salt Lake City, Utah

The University of Melbourne, Melbourne, Not set

Medical University of Graz, Graz, Not set

Innsbruck Medical University, Innsbruck, Not set

Kepler University Hospital, Linz, Not set

Medical University of Vienna, Vienna, Not set

Krankenhaus Nord Vienna North Hospital, Vienna, Not set

Institute of Cardiology Porto Alegre, Porto Alegre, Not set

Heart Institute University of São Paulo, São Paulo, Not set

Instituto Dante Pazzanese de Cardiologia, Vila Mariana, Not set

St. Boniface General Hospital, Winnipeg, Manitoba

Horizon Health Network - Saint John Regional Hospital, Saint John, New Brunswick

NL Health Services, St. John's, Newfoundland and Labrador

Hamilton General Hospital, Hamilton, Ontario

London Health Sciences, London, Ontario

University of Ottawa Heart Institute, Ottawa, Ontario

Health Sciences North, Sudbury, Ontario

Sunnybrook Health Sciences, Toronto, Ontario

Toronto General Hospital, Toronto, Ontario

Montreal Heart Institute, Montréal, Quebec

University Hospital of Montreal, Montréal, Quebec

Royal Victoria Hospital, Montréal, Quebec

Institut Universitaire de Cardiologie et de Pneumologie de Québec, Ste Foy, Quebec

Hopital Sacre-Coeur, Montréal, Not set

Fraser Clinical Trials, New Westminster, Not set

Fuwai Hospital China, Beijing, Beijing

Jilin Heart Hospital China, Changchun, Jilin

Ruijin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai

Teda Hospital Tianjin China, Tianjin, Tianjin

University Hospital Dubrava, Zagreb, Not set

University Hradec Králové, Hradec Králové, Not set

General University Hospital, Prague, Nové Město, Not set

Aalborg University Hospital, Aalborg, Not set

Rigshospitalet, Copenhagen, Not set

Universitäts-Herzzentrum Bad Krozingen Freiburg, Bad Krozingen, Baden-Wuerttemberg

HDZ NRW Bad Oeynhausen Germany, Bad Oeynhausen, Not set

Deutsches Herzzentrum der Charite, Berlin, Not set

Essen University, Duisburg, Not set

Duisburg Heart Center, Duisburg, Not set

Dusseldorf University, Düsseldorf, Not set

University Hospital Erlangen, Erlangen, Not set

Essen University, Essen, Not set

Frankfurt University, Frankfurt, Not set

University Hospital of Giessen and Marburg, Gießen, Not set

University Medical Center of Göttingen, Göttingen, Not set

Jena University Hospital, Jena, Not set

Heart Center Herzzentrum, Leipzig, Leipzig, Not set

Robert-Bosch-Hospital Stuttgart Germany, Stuttgart, Not set

Krankenhaus der Barmherzigen Brüder Trier, Trier, Not set

G Kuppuswamy Naidu Memorial Hospital (GKNM), Coimbatore, Tamil Nadu

Star Hospitals - Hyderabad, India, Hyderabad, Telangana

Rambam Health Care Campus, Haifa, Not set

Anthea Hospital, Bari, Not set

Humanitas Gavazzeni of Bergamo, Bergamo, Not set

Fondazione Poliambulanza, Brescia, Not set

Maria Cecilia Hospital GVM, Cotignola, Not set

Careggi University Hospital, Florence, Not set

European Hospital, Roma, Not set

Universita' Cattolica del Sacro Cuore, Roma, Not set

Ospedale Le Molinette, Torino, Torino, Not set

Tokyo Medical and Dental University, Bunkyō-Ku, Tokyo

Saitama Medical University Japan, Saitama, Not set

Seoul National University Hospital, Seoul, Not set

Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seúl, Not set

Maastricht University Medical Centre, Maastricht, Not set

Acibadem-Sistina Hospital, Skopje, Not set

Medical University of Silesia, Katowice, Not set

Zbigniew Religa Lower Silesian Heart Disease Centre, Zabrze, Not set

University Hospital Coimbra, Coimbra, Not set

Centro Hospitalar Lisboa Ocidental, Lisboa, Not set

Centro Hospitalar e Universitário Sao João, Porto, Not set

National Research Medical Center of the Russian Academy of Sciences - Tomsk, Russia, Tomsk, Not set

Dedinje Cardiovascular Institute, Belgrade, Not set

National University of Singapore, Singapore, Not set

Hospital Universitario del Vinalopo, Elx, Alicante

Hospital Clinic de Barcelona, Barcelona, Not set

Hospital Clinico de San Carlos, Madrid, Not set

NavarraBiomed, Pamplona, Not set

Sahlgrenska University Hospital, Gothenburg, Not set

National Taiwan University Hospital, Zhongzheng, Taipei

Oxford University Hospitals NHS Trust, Multiple Locations, Oxford

NHS Golden Jubilee, Clydebank, Not set

The Royal Infirmary of Edinburgh, Edinburgh, Not set

Hull University Hospitals, Hull, Not set

University Hospitals of Leicester, Leicester, Not set

Liverpool Heart and Chest Hospital Foundation Trust, Liverpool, Not set

Guy's and St Thomas' NHS Foundation Trust, London, Not set

Imperial College Healthcare NHS Trust, London, Not set

St George's University Hospitals, London, Not set

Manchester University NHS Trust, Manchester, Not set

South Tees Hospitals NHS Trust, Middlesbrough, Not set

Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, Not set

Royal Wolverhampton NHS Trust, Wolverhampton, Not set

Conditions: Heart Diseases, Coronary Artery Disease, Coronary Artery Bypass Grafting

Learn More ›

Insertable Cardiac Monitor-Guided Early Intervention to Reduce Atrial Fibrillation Burden Following Catheter Ablation

NCT04922281

Recruiting

To prospectively investigate the efficacy of an insertable cardiac monitor-guided atrial fibrillation (AF) management in reducing subsequent AF burden in patients with persistent or paroxysmal AF undergoing atrial catheter ablation (CA).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/23/2024

Locations: University of Rochester Medical Center, Rochester, New York

Conditions: Atrial Fibrillation, Cardiovascular Diseases, Heart Diseases, Arrhythmias, Cardiac, Pathologic Processes

Learn More ›

Smartphone Twelve-Lead ECG Utility In ST-Elevation Myocardial Infarction II

NCT06271577

Recruiting

AliveCor (www.alivecor.com) has developed several electrocardiogram (ECG) devices that interface with iOS and Android smartphones and tablets via various Kardia apps. The current Kardia family of devices can measure single lead and six limb-lead ECGs, depending on the device. KardiaMobile, KardiaMobile 6L, and KardiaMobile Card have FDA clearance for ECG rhythm recording. A modified single-lead Kardia smartphone 12-lead ECG was previously validated in the multicenter ST LEUIS study for the diagnosis of ST-Segment Elevation Myocardial Infarction (STEMI) and Non-ST-Elevation Myocardial Infarction (NSTEMI). Recently, AliveCor developed a new device: AliveCor (AC) 12-lead (12L) ECG System to record simultaneously 4 leads of ECG and then generate complete 12-lead ECGs. A previous protocol at the University of Oklahoma involved 200 subjects with early prototypes of the AC 12L device with the specific aim to validate that it accurately generated 12-lead ECGs as compared to simultaneously acquired FDA-cleared 12-lead ECGs. The prototype version of the AliveCor 12L ECG System simultaneously measured four channels of ECG (leads I, II, V2, V4), calculated the remaining limb leads as is standard for 12-lead ECGs (Leads III, aVR, aVL, aVF) and synthesized the remaining 4 precordial ECG leads (V1, V3, V5, V6). This protocol will serve to validate the production version of the system against standard 12-Lead ECGs for the diagnosis of STEMI and NSTEMI in patients admitted to the Emergency Department or directly to the Cardiac Cath Lab for the evaluation of chest pain. It is anticipated that the waveforms for each of the 12 leads from the AC 12L ECG System will be highly correlated with the corresponding leads from the comparator commercially available 12-lead ECG devices used at participating sites. The purpose of this study is to clinically validate that the four-channel AC 12L ECG device can enable the diagnosis of STEMI and NSTEMI in a non-inferior manner to existing 12-lead ECG devices. Read Less

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/03/2024

Locations: Mayo Clinic, Rochester, Minnesota +1 locations

Conditions: Myocardial Infarction, Ischemia, Myocardial Ischemia, Heart Diseases, Cardiovascular Diseases, Vascular Diseases, Heart Attack, Heart Failure

Learn More ›

Immunomodulatory Effects of PCSK9 Inhibition

NCT05720156

Recruiting

Cardiovascular disease (CVD) represents the leading cause of death worldwide. While medications, such as statins, significantly reduce atherosclerotic CVD (ASCVD) risk by lowering low density lipoprotein levels, they may also have pleiotropic effects on inflammation. The immunomodulatory effects of these medications are relevant to ASCVD risk reduction given that inflammation plays a central role in atherosclerotic plaque formation (atherogenesis) and influences the development of vulnerable pla... Read More

Gender:

All

Ages:

Between 18 years and 85 years

Trial Updated:

05/08/2024

Locations: Massachusetts General Hospital, Boston, Massachusetts

Conditions: Atherosclerotic Cardiovascular Disease, Cardiovascular Diseases, Atherosclerosis, Arterial Inflammation, Vascular Diseases, Vascular Disease, Peripheral, Vascular Calcification, High Cholesterol/Hyperlipidemia, Heart Diseases, Heart Attack, Stroke, Cerebrovascular Accident, Carotid Artery Diseases, Carotid Atherosclerosis, Transient Ischemic Attack

Learn More ›

13 - 24 of 36